The Global EXPAND study presented Oct. 16 during TCT 2020 is the first contemporary report of one-year outcomes in patients with both primary and secondary mitral regurgitation (MR) treated with the third generation MitraClip NTR and XTR systems.

Saibal Kar, MD, FACC, et al., enrolled 1,041 subjects at 57 centers in the U.S. and Europe. Key outcome measures included MR severity, procedural outcomes, major adverse events, survival and heart failure hospitalization and quality of life and functional assessments at one year.

Overall results found significant MR reduction from baseline through one year was maintained. “Results indicate that MR ≤1+ is being achieved more often with the third generation MitraClip, compared with prior generations, which is maintained at one year,” said Kar et al.

Additionally, investigators noted significant reduction in MR was associated with sustained improvements in quality of life and heart failure symptoms. “Introduction of additional clip size, XTR and improvements in the delivery system resulted in greater reduction in MR without an increase in adverse events,” they add.

Clinical Topics: Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Interventions and Structural Heart Disease, Mitral Regurgitation

Keywords: TCT20, Transcatheter Cardiovascular Therapeutics, Percutaneous Coronary Intervention, Mitral Valve, Mitral Valve Insufficiency

< Back to Listings